Hanmi Science Co., Ltd.: Business Overview, Financials & Competitive Analysis
Hanmi Science Co., Ltd. scores 6/10 on the AskCyborg Cyborg Score (Solid). Established Asian pharma player with diversified product portfolio and strategic partnerships, facing near-term profitability headwinds despite revenue stability. In 2023, the company achieved 1.25 trillion KRW in revenue with 19.30% growth and earnings of 115.12 billion with 66.34% growth. However, recent 2024 data shows deceleration with revenue growth.
What is Hanmi Science Co., Ltd.'s industry? Hanmi Science Co., Ltd. (hanmiscience.co.kr) operates in Pharmaceuticals and Healthcare. AskCyborg classifies Hanmi Science Co., Ltd. under Pharmaceuticals and Healthcare in its company registry.
Hanmi Science is a holding company with two core subsidiaries: Hanmi Pharmaceutical, which develops and produces medicines, and Online Pharm, a drug wholesaler. The company develops drugs in the areas of diabetes and ...
Cyborg Score thesis
Established Asian pharma player with diversified product portfolio and strategic partnerships, facing near-term profitability...
Read the full analyst-debate transcript →Get the Latest Hanmi Science Co., Ltd. Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeHanmi Science Co., Ltd. Overview
Pro stress-test →Hanmi Science is a holding company with two core subsidiaries: Hanmi Pharmaceutical, which develops and produces medicines, and Online Pharm, a drug wholesaler. The company develops drugs in the areas of diabetes and anti-cancer, as well as children's and adult's bowel preparation and cold medicines, and cephalosporin antibiotics.
Strategic Profile
Pro stress-test →The company operates through its pharmaceutical manufacturing subsidiary and drug distribution network, actively developing new drugs in recent years. Hanmi recently partnered with Merck & Co on April 4, 2024, demonstrating its strategic focus on expanding its drug development pipeline and global partnerships.
Competitive Landscape
Pro stress-test →Hanmi Science competes in the South Korean and broader Asian pharmaceutical market against multinational pharma giants and local competitors. Its competitive advantage lies in specialized therapeutic areas (diabetes, oncology, GI) and a vertically integrated distribution model through Online Pharm. The company faces competition from larger multinational players with greater R&D budgets and global reach.
Industry Context
Hanmi Science Co., Ltd. operates in Pharmaceuticals and Healthcare.
Key facts
Founded: 1973 · Headquarters: Seoul, South Korea · Employees: 422 · Revenue: $941.7M · Market cap: $1.72B